Acoramidis对ATTR-CM复发及累积心血管结局的影响:ATTRibute-CM探索性分析
该研究为ATTRibute-CM及其开放标签扩展的事后探索性复发事件分析,评估acoramidis对转甲状腺素蛋白淀粉样心肌病(ATTR-CM)累积心血管结局的影响。结果显示,acoramidis显著降低30个月内心血管死亡或复发性心血管住院的累积风险(HR 0.51,95%CI 0.43-0.62,P<0.0001),每100例治疗患者避免53次事件。
要点
- Acoramidis显著降低ATTR-CM患者30个月内累积心血管事件负担。
- 近四分之一累积心血管事件发生于最初6个月内,提示早期评估与治疗的重要性。
- 持续acoramidis治疗至42个月显著降低心血管死亡风险(HR 0.55)。
核心结论
- Acoramidis显著降低ATTR-CM患者30个月内累积心血管结局负担。
- acoramidis组较安慰剂组第1个月即观察到数值上更少的累积事件,且差异随时间逐渐增大。
研究设计与样本
- ATTRibute-CM研究及其开放标签扩展的事后探索性复发事件分析。
- 改良意向治疗人群:acoramidis组n=409,安慰剂组n=202。
- 采用改良Andersen-Gill模型估计平均累积事件及组间差异。
主要发现
- Acoramidis显著降低30个月内CVM或复发性CVH的累积风险(HR 0.51;95%CI 0.43-0.62;P<0.0001)。
- 19%的CVM或复发性CVH事件、22%的CVH发生于最初6个月内。
- 第30个月时每100例治疗患者避免53次事件(95%CI 29-79)。
- 第42个月时,持续acoramidis组较安慰剂转acoramidis组CVM降低(HR 0.55;95%CI 0.39-0.79;P=0.0011)。
- 30个月内复发性CVH的年化频率显著降低(相对风险比0.50;95%CI 0.35-0.69;P<0.0001)。
临床怎么用
- ATTR-CM累积事件负担可能早期出现,应重视及时评估、诊断和治疗。
局限性
- 本研究为事后探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive disease with a significant burden of recurrent cardiovascular (CV) events. Acoramidis, an approved oral therapy for ATTR-CM, achieves early, near-complete (≥90%) TTR stabilization. In the phase 3 ATTRibute-CM (Efficacy and Safety of Acoramidis in Participants with Transthyretin Amyloid Cardiomyopathy) study, acoramidis significantly reduced the composite of all-cause mortality or first CV-related hospitalization (CVH), with an effect observed at month 3. Its efficacy on the burden of cumulative CV outcome events has not been reported. OBJECTIVES: This study was a post hoc exploratory recurrent-event analysis of the efficacy of acoramidis on the cumulative incidence of CV outcomes from ATTRibute-CM and its open-label extension. METHODS: Cumulative incidences of centrally adjudicated CV-related mortality (CVM) or recurrent CVH (first and, if applicable, subsequent CVH), recurrent CVH alone (month 30), and CVM (month 42) were measured in the modified intention-to-treat population (acoramidis, n = 409; placebo, n = 202). Mean cumulative events by treatment, and the difference between treatment groups were estimated by using a modified Andersen-Gill model. RESULTS: Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through month 30 vs placebo (HR: 0.51; 95% CI: 0.43-0.62; P < 0.0001). A notable proportion of CV outcome events (19% of CVM or recurrent CVH events, 22% of CVH) occurred within the first 6 months. Numerically fewer cumulative events were observed with acoramidis compared with placebo at month 1, and the difference increased progressively, resulting at month 30 in 53 events avoided per 100 treated participants (95% CI: 29-79). At month 42, CVM was reduced with continuous acoramidis vs placebo-to-acoramidis (HR: 0.55; 95% CI: 0.39-0.79; P = 0.0011). The annualized frequency of recurrent CVH was significantly decreased through month 30 (relative risk ratio: 0.50; 95% CI: 0.35-0.69; P < 0.0001). CONCLUSIONS: Acoramidis significantly reduced the cumulative burden of CV outcomes in ATTR-CM over 30 months. Numerically fewer events were observed with acoramidis vs placebo by month 1, and the difference increased progressively over time, resulting in 53 events avoided per 100 treated patients at month 30. Almost one-fourth of the cumulative CV events occurred within the first 6 months. These exploratory findings suggest that cumulative event burden may occur early, highlighting the importance of timely evaluation, diagnosis and treatment in ATTR-CM.
引用
- Masri A, Judge DP, Ruberg FL, et al. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. J Am Coll Cardiol. 2025. PMID: 41143759. doi:10.1016/j.jacc.2025.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。